Lupin launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the US market following FDA ANDA approval.
The product is bioequivalent to AstraZeneca's Xigduo® XR and comes in four dosage strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg.
This launch strengthens Lupin's position in the anti-diabetic therapeutic area and expands its US generic product portfolio.